GUJARAT THEMIS BIOSYN LTD Fair Value
GUJTHEM · Healthcare · Current price ₹411.6
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹35 | 16% ROE fading to 13% over ~20 yrs, on ₹26 book |
| Relative P/E | ₹167 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹50 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is GUJARAT THEMIS BIOSYN LTD undervalued?
DocStoX estimates the fair value of GUJARAT THEMIS BIOSYN LTD at ₹74 per share, versus the current market price of ₹412. That puts the stock about -81.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹35), Relative P/E (₹167), Graham floor (₹50). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹35 (bear) to ₹74 (base) to ₹167 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on GUJARAT THEMIS BIOSYN LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.